MedTrace Logo

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

NCT06028633 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-09-13

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of albumin-bound paclitaxel-lenvatinib-pembrolizumab in advanced nonsquamous NSCLC patients after progression to first-line anti-PD-1/L1 inhibitor with platinum-doublet chemotherapy. All participants will be given with albumin-bound paclitaxel, lenvatinib and pembrolizumab.

Conditions

  • Advanced Non-squamous Non-small-cell Lung Cancer
  • Recurrent Non-Squamous Non-Small Cell Lung Cancer
  • Metastatic Non-squamous Non Small Cell Lung Cancer

Interventions

DRUG

pembrolizumab

pembrolizumab 200mg IV on day 1 for every 3 weeks

DRUG

lenvatinib

lenvatinib 8mg taken orally every day

DRUG

albumin-bound paclitaxel

albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks

Sponsors & Collaborators

Principal Investigators

  • Shikai Wu · Peking Univerisity First Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2024-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06028633 on ClinicalTrials.gov